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Macrophages, which belong to the immune system, are increasingly being recognized for their contribution
to metabolic regulation. In two studies by Kang et al. (2008) and Odegaard et al. (2008) in this issue of Cell
Metabolism, we learn that alternative activation (M2a) of resident macrophages in liver and adipose tissue
depends highly on PPARd/b activity, leading to improved fatty acid metabolism and insulin sensitivity.Born from myeloid bone marrow cells,
macrophages circulate in the blood as
monocytes and migrate within tissues ei-
ther to remain in the tissues, such as res-
ident Kupffer cells in the liver, or as a de-
fense mechanism infiltrating tissues in an
inflammatory context. Classical activation
of macrophages is promoted by secre-
tions from T helper 1 cells, particularly
IFN-g, and such activated macrophages,
also called M1, are proinflammatory and
have high microbicidal properties. Alter-
native activation is mediated by macro-
phage exposure to IL-4 and/or IL-13 cyto-
kines. This induces in the macrophage
a distinctive gene expression program
(M2a profile) that instead limits inflamma-
tion through reduced proinflammatory
cytokine secretion, synthesis of trophic
factors such as polyamine and proline,
and high endocytosis activities (Gordon,
2003). In the present issue, Kang et al.
(2008) and Odegaard et al. (2008) demon-
strate that the nuclear receptor peroxi-
some proliferator-activated receptor d/b
(PPARd/b) plays a prime role in controlling
the alternative activation of adipose tissue
macrophages (ATMs) and Kupffer cells in
the liver.
Low-grade systemic inflammation in
obese patients is a feature that contrib-
utes to the appearance of insulin resis-
tance. Interestingly, obesity is accompa-
nied by an increased infiltration of ATMs,
possibly summoned by damaged or
dead hypertrophic adipocytes. Whereas
the phenotype of ATMs present in lean
animals corresponds to an M2a profile,
the cytokines released in adipose tissue
from obese animals indicate M1 macro-
phage infiltration (Lumeng et al., 2007).PPARs are transcription factors with
pleiotropic activities, linking macrophage
and metabolism. They are at the heart of
lipid metabolism, controlling lipid trans-
port, use, and storage. Due to its impor-
tance in adipogenesis and the beneficial
activity of specific synthetic agonists in
insulin resistance, PPARg has remained
a privileged target for fundamental as
well as applied research. The importance
of PPARg in macrophages has been re-
cently highlighted by a series of papers
showing the role of PPARg in the switch
of macrophage phenotype from M1 to
M2a and its consequences on insulin sen-
sitivity (Bouhlel et al., 2007; Hevener et al.,
2007; Odegaard et al., 2007). PPARd/b is
the least known PPAR, but its importance
in regulating macrophage activity and
acting on various aspects of metabolic
syndrome has been recently emphasized
(Barish et al., 2008). The two reports high-
lighted herein provide a new twist by
showing that polarization ofmacrophages
toward M2a is PPARd/b dependent, and
explore how this affects two major meta-
bolic tissues, the adipose tissue and the
liver.
Kang et al. (2008) first demonstrate that
adipocytes as well as hepatocytes locally
produce IL-4 and IL-13 cytokines, estab-
lishing a reciprocal functional crosstalk
between parenchymal cells and resident
immune cells (e.g., ATMs and Kupffer
cells). IL-4/IL-13 exposure leads to
PPARd/b activation in macrophages, pos-
sibly through a direct transcriptional
increase of the PPARd/b (Ppard/b) gene
via a STAT6 binding site in the PPARd/
b promoter (Kang et al., 2008). The data
of Odegaard et al. (2008) rather suggestCell Metaboreceptor activation via binding of ligands
such as unsaturated fatty acids. This is
consistent with the influx of fatty acids
that may accompanymacrophage activa-
tion in vivo. These mechanisms are obvi-
ously complementary but cannot explain
the full PPARd/b activity observed in cul-
tured macrophages upon IL-4 or IL-13
exposure. An interesting hypothesis that
remains to be explored is the possible
production of an endogenous ligand
by macrophages exposed to these cyto-
kines. Alternatively, cytokines could
mediate a posttranslational modification
of PPARd/b, an activation process still
poorly explored for PPARd/b.
Both papers then demonstrate that the
resulting PPARd/b activation is responsi-
ble for the gene expression program
corresponding to M2a macrophages. A
direct activity of PPARd/b on each of the
genes reflecting the M2a phenotype is
possible, as PPAR response elements
have been found in several of these genes
and have been demonstrated to be
functionally active for arginase 1 (Arg1).
However, thus far, activation of STAT6
was reputed to be the main factor linking
IL-4/IL-13 signaling to gene expression
responses. Thus, rather than multiple
and distributive activity of PPARd/b on
a series of genes, it would be interesting
to look at STAT6 activity upon PPARd/b
activation that could explain the coordi-
nate regulation of a full set of genes.
Such experiments would also shed light
on macrophage polarity regulation.
In both reports, the metabolic conse-
quences of PPARd/b deletion in macro-
phages are impaired glucose tolerance
and exacerbation of insulin resistancelism 7, June 2008 ª2008 Elsevier Inc. 467
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Both reports observed marked fatty liver
in mice carrying a PPARd/b deletion in
macrophages, with increased lipogenesis
and decreased oxidative metabolism.
However, this phenotype is associated
with impairment of insulin signaling in the
liver in Odegaard et al. (2008), but not in
Kang et al. (2008). The differences are
more important concerning the character-
ization of white adipose tissue. Odegaard
et al. (2008), while observing an impaired
response to insulin, found little metabolic
change but higher adiposity and larger
adipocytes. Kang et al. (2008), in contrast,
found reduced insulin sensitivity together
with increased lipolysis, consistent with
their observation of decreased adiposity
and small adipocytes. At first glance,
these differences are difficult to explain.
They might be due to slightly different
mouse models, Lys-Cre-driven specific
deletion of PPARd/b in macrophages
(Kang et al., 2008) versus PPARd/b/
bone marrow transplantation in irradiated468 Cell Metabolism 7, June 2008 ª2008 Elswild-type mice (Odegaard et al., 2008). In
the latter, all hematopoietic cells are af-
fected by the deletion, possibly affecting
systemic responses. Thus, even though
the two reports elegantly demonstrate
that hepatocytes as well as adipocytes
modify their gene expression program
when cocultured with macrophages, fur-
ther work is needed to clarify the relative
importance of tissue-resident macro-
phages versus systemic inflammation.
Thesedata also raise the question of the
respective roles of PPARd/b and PPARg.
In line with a previous report (Welch
et al., 2003), Odegaard et al. (2008) pro-
pose that PPARd/b and PPARg have
both distinct and overlapping activities in
ATMs. In contrast, expression of PPARg
in Kupffer cells is very low,whichmight ex-
plain why macrophage PPARd/b deletion
producesmorepronounced effects in liver
versus adipose tissue. However, this hy-
pothesis needs to be further experimen-
tally addressed. This should also give the
opportunity to revisit the results obtainedevier Inc.in macrophages exposed to IL-4 and so
far attributed solely to increased PPARg
activity (Huang et al., 1999).
Regardless of the few discrepancies,
these two reports are important for in-
creasing our understanding of (1) the
alternative activation process for macro-
phage function, (2) macrophage-paren-
chyma crosstalk in metabolic regulations,
and (3) the functions of PPARd/b, the
PPAR isotype with the broadest expres-
sion and activity but about which the least
is known (Figure 1). Both papers end on an
optimistic note about the future of target-
ing PPARd/b and/or Kupffer cells for con-
trolling insulin resistance. A benefit for
metabolic syndrome is likely, but also
likely is a threat in terms of liver fibrosis. In-
deed, fibrosis is a major complication of
nonalcoholic hepatic steatosis, such as
can be encountered in metabolic syn-
drome, and can ultimately lead to cirrhosis
and hepatocellular carcinoma (Farrell and
Larter, 2006).M2macrophages arepartic-
ularly active in elaborating extracellularFigure 1. PPARd/b in the Macrophage-Parenchymal Cell Crosstalk
Kupffer cells in the liver (left panel) and adipose tissue macrophages (ATM) in adipose tissue (right panel) respond to local IL-4/IL-13 cytokines, in part produced
by hepatocytes and adipocytes, as shown by the downward arrows. The subsequent activation of PPARd/b in Kupffer cells and both PPARd/b and PPARg in
adipose tissue allows the macrophage to adopt an M2 profile. Through signals yet to be uncovered, M2 activities contribute to ameliorate insulin sensitivity
and lipid metabolism in the parenchymal cells (upward arrows). An expected downside of M2 activity in the liver is fibrosis (gray arrow). In adipose tissue, the
specific and overlapping roles of PPARd/b and PPARg remain to be determined and might differ in lean and in obese individuals. In the present issue, Odegaard
et al. (2008) propose that adipose tissue from lean animals is rich in M2 macrophages and that this profile is maintained by the M2 macrophages themselves
through PPARd/b activity (left ‘‘adipose tissue’’ panel). In addition, adipose tissue from obese animals is infiltrated by M1 macrophages, and PPAR activities
would contribute to metabolic regulation through turning them to the M2 type (right ‘‘adipose tissue’’ panel; see Kang et al. [2008] and Odegaard et al. [2008]
in this issue). Illustration by Matthew Hall.
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Previewsmatrix and have proproliferative and
proangiogenic activities. Consistently,
the upregulation of IL-13 has been linked
to progression of liver fibrosis (Reiman
et al., 2006). In this context, and following
the two reports highlighted herein, it
becomes a high priority to evaluate how
modifying Kupffer cell phenotype, via
PPARd/b agonists (or antagonists) or
other means, would affect the evolution
and prognosis of nonalcoholic hepatic
steatosis.
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sources, whereas ezetimibe (trade names
Zetia, Ezetrol, and Ezemibe), a recently
approved drug, does so efficiently.
When coadministered with a statin, ezeti-
mibe reduces patients’ serum LDL cho-
lesterol levels more than statin alone.
Ezetimibe is known to block Niemann-
Pick C1-like 1 (NPC1L1), although the
mechanism of this action is unclear. A new
study by Ge, Wang, and colleagues (Ge
et al., 2008) in this issueofCellMetabolism
shows that NPC1L1 mediates cholesterol
uptake via vesicular endocytosis and that
ezetimibe inhibits cholesterol absorption
by blocking the internalization of NPC1L1
protein.
Cell MetaboLumeng, C.N., Bodzin, J.L., and Saltiel, A.R.
(2007). J. Clin. Invest. 117, 175–184.
Odegaard, J.I., Ricardo-Gonzalez, R.R., Goforth,
M.H., Morel, C.R., Subramanian, V., Mukundan,
L., Red Eagle, A., Vats, D., Brombacher, F., Fer-
rante, A.W., and Chawla, A. (2007). Nature 447,
1116–1120.
Odegaard, J.I., Ricardo-Gonzalez, R.R., Red Ea-
gle, A., Vats, D., Morel, C.R., Goforth, M.H., Subra-
manian, V., Mukundan, L., Ferrante, A.W., and
Chawla, A. (2008). Cell Metab. 7, this issue, 496–
507.
Reiman, R.M., Thompson, R.W., Feng, C.G., Hari,
D., Knight, R., Cheever, A.W., Rosenberg, H.F.,
and Wynn, T.A. (2006). Infect. Immun. 74, 1471–
1479.
Welch, J.S., Ricote, M., Akiyama, T.E., Gonzalez,
F.J., and Glass, C.K. (2003). Proc. Natl. Acad.
Sci. USA 100, 6712–6717.C.C.)
cks intestinal cholesterol absorp-
hows that non-lipoprotein-bound
internalization of the NPC1L1/cho-
Ezetimibe was originally identified as
a weak inhibitor of the enzyme acyl-coen-
zymeA:cholesterol acyltransferase (ACAT).
There are two ACAT genes, ACAT1 and
ACAT2, which encode two enzymes with
similar biochemical properties. In various
cell types, ACAT1 converts excess cellu-
lar cholesterol to cholesteryl esters (CEs)
for storage (Chang et al., 2006), while in
intestinal enterocytes, ACAT2 produces
CEs that become part of the lipid cargo
present in the lipoproteins known as chy-
lomicrons (Buhman et al., 2000). Once as-
sembled, chylomicrons are secreted into
the bloodstream for delivery of lipid cargo
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not target ACAT. In animals, ezetimibe
efficiently blocks intestinal cholesterol
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